Introduction
Triglyceride and Genetics in History
Classical Fredrickson Phenotypes
Genetic Architecture of TG-related Phenotypes
HyperTG Christmas Tree
Genetic Testing
Genetic Testing : Validity & Utility Issues
Hypertriglyceridemia vs. Hypercholesterolemia
Hypertriglyceridemia vs. Hypercholesterolemia
Hypertriglyceridemia vs. Hypercholesterolemia
Exogenous & Endogenous Pathways
Systems & Molecular Approaches
TG-Associated Genes
Proportion of Variation Explained by Clinical Variables
GWAS vs Resequencing the Extremes
Gene x Gene and Gene x Environment
Severe HyperTG
Mendelian Randomization
APOA5 & Mendelian Randomization
APOA5 & Mendelian Randomization
Risk Associated with HyperTG
Causes of Very Severe HyperTG
Risk of Pancreatitis Associated with HyperTG
FCS Clinical Expression
Risk Associated with Very Severe HyperTG
Risk Associated with Very Severe HyperTG
The « ROC POP » Approach
Emerging Therapies for HyperTG
Emerging Treatments of Severe HyperTG
Omics and Emerging TG-Lowering Therapies
Glybera: AAV2-LPL S447X
Glybera Gene Replacement Therapy
Glybera Mechanism of Action
Fasting TG Decreased After 12 Weeks
Ultracentrifugation Data at > 5 Months
3H-Chylomicron Clearance 14 Weeks
ISIS-APOCIIIRx Anti-Sense Therapy
Apolipoprotein C-III is a Key regulator
ISIS-APOCIIIRx Anti-Sense Therapy
Phase 2 Multicenter Randomized Double-Blind Placebo
ISIS-APOCIIIRx Treatment Reduced Fasting Fasting ApoC-III Levels
ISIS-APOCIIIRx Treatment Reduced Fasting Triglyceride Levels
ISIS-APOCIIIRx Treatment Reduced Fasting Non-HDL-C Levels
ISIS-APOCIIIRx Treatment Improved Overall
Emerging Therapies for Very Severe HyperTG
DGAT1, Chylomicron production & Pathophysiology
DGAT Biochemical Pathway
LCQ908 FCS PoC Study Schematic
Fasting Triglyceride Levels with LCQ908
Effects of LCQ908 (20 mg) on Triglyceride
Peptide Linker Technology (CAT-2003)
CAT-2003: Inactive Until Entering the Target Cell
CAT-2003 Activates Lipoprotein Lipase (LPL)
CAT-2003 Clinical Status
Severe HyperTG: Lessons Learned
Severe HyperTG: Future directions
1 of 56